Therapeutic potential of the chemokinereceptor duo fractalkine/CX3CR1: An update

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 6, 2012, Pages 613-618

  D'Haese, Jan G ^a   Friess, Helmut ^a   Ceyhan, Güralp O ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

cancer; CX3CL1; CX3CR1; fractalkine; inflammation; neuropathic pain; therapeutic target

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE; CHEMOKINE RECEPTOR; CX3CL1 PROTEIN, HUMAN; CX3CR1 PROTEIN, HUMAN;

ALLERGIC ASTHMA; ALZHEIMER DISEASE; BRAIN ISCHEMIA; CLINICAL PRACTICE; CROHN DISEASE; DEPRESSION; FIBROGENESIS; HUMAN; INFLAMMATION; KIDNEY DISEASE; LIVER CELL CARCINOMA; MEDLINE; MOOD DISORDER; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN; PANCREAS DISEASE; PARKINSON DISEASE; REVIEW; RHEUMATOID ARTHRITIS; ANIMAL; METABOLISM; NEOPLASM;

ANIMALS; CHEMOKINE CX3CL1; HUMANS; INFLAMMATION; NEOPLASMS; PAIN; RECEPTORS, CHEMOKINE;

EID: 84861308990     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.682574     Document Type: Review

References (35)

1. Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997;385(6617):640-4
2. D'Haese JG, Demir IE, Friess H, Ceyhan GO. Fractalkine/CX3CR1: Why a single chemokine-receptor duo bears a major and unique therapeutic potential. Expert Opin Ther Targets 2010;14(2):207-19
3. Tong N, Perry SW, Zhang Q, et al. Neuronal fractalkine expression in HIV-1 encephalitis: Roles for macrophage recruitment and neuroprotection in the central nervous system. J Immunol 2000;164:1333-9 (Pubitemid 30067246)
4. Verge GM, Milligan ED, Maier SF, et al. Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur J Neurosci 2004;20(5):1150-60 (Pubitemid 39233569)
5. Deiva K, Geeraerts T, Salim H, et al. Fractalkine reduces N-methyl-d-aspartateinduced calcium flux and apoptosis in human neurons through extracellular signal-regulated kinase activation. Eur J Neurosci 2004;20(12):3222-32 (Pubitemid 40013533)
6. Meucci O, Fatatis A, Simen AA, et al. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci USA 1998;95(24):14500-5 (Pubitemid 28549396)
7. Medina-Contreras O, Geem D, Laur O, et al. CX3CR1 regulates intestinal macrophage homeostasis, bacterial translocation, and colitogenic Th17 responses in mice. J Clin Investig 2011;121(12):4787-95
8. Mionnet C, Buatois V, Kanda A, et al. CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung. Nat Med 2010;16(11):1305-12
9. Broux B, Pannemans K, Zhang X, et al. CX(3)CR1 drives cytotoxic CD4(+) CD28(-) T cells into the brain of multiple sclerosis patients. J Autoimmun 2012;38(1):10-9
10. Tarrant TK, Liu P, Rampersad RR, et al. CX3CR1 deficient mice have decreased Th17 and antigen-specific humoral responses in the collagen induced arthritis (CIA) model. Arthritis Rheum 29 Nov 2011
11. Bressan E, Peres KC, Tonussi CR. Evidence that LPS-reactive arthritis in rats depends on the glial activity and the fractalkine-TNF-alpha signaling in the spinal cord. Neuropharmacology 2012;62(2):947-58
12. Aoyama T, Inokuchi S, Brenner DA, Seki E. CX3CL1-CX3CR1 interaction prevents carbon tetrachloride-induced liver inflammation and fibrosis in mice. Hepatology (Baltimore, Md) 2010;52(4):1390-400
13. Shimizu K, Furuichi K, Sakai N, et al. Fractalkine and its receptor, CX3CR1, promote hypertensive interstitial fibrosis in the kidney. Hypertens Res 2011;34(6):747-52
14. Karlmark KR, Zimmermann HW, Roderburg C, et al. The fractalkine receptor CXCR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology (Baltimore, Md) 2010;52(5):1769-82
15. Garcia-Alvarez M, Berenguer J, Guzman-Fulgencio M, et al. High plasma fractalkine (CX3CL1) levels are associated with severe liver disease in HIV/HCV co-infected patients with HCV genotype 1. Cytokine 2011;54(3):244-8
16. Staniland AA, Clark AK, Wodarski R, et al. Reduced inflammatory and neuropathic pain and decreased spinal microglial response in fractalkine receptor (CX3CR1) knockout mice. J Neurochem 2010;114(4):1143-57
17. Willemen HL, Eijkelkamp N, Wang H, et al. Microglial/macrophage GRK2 determines duration of peripheral IL-1beta-induced hyperalgesia: Contribution of spinal cord CX3CR1, p38 and IL-1 signaling. Pain 2010;150(3):550-60
18. Gaudin F, Nasreddine S, Donnadieu AC, et al. Identification of the chemokine CX3CL1 as a new regulator of malignant cell proliferation in epithelial ovarian cancer. PloS one 2011;6(7):e21546
19. Kim M, Rooper L, Xie J, et al. Fractalkine receptor CX3CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells. Mol Cancer Res 2012;10(1):11-24
20. Li F, Wang Z, Liu Y, Li J. Down-regulation of fractalkine inhibits the in vitro and in vivo angiogenesis of the hepatocellular carcinoma HepG2 cells. Oncol Rep 2010;24(3):669-75
21. Sciume G, Soriani A, Piccoli M, et al. CX3CR1/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-beta1. Neuro-oncol 2010;12(7):701-10
22. Erreni M, Solinas G, Brescia P, et al. Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1. Eur J Cancer 2010;46(18):3383-92
23. Lee S, Varvel NH, Konerth ME, et al. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am J Pathol 2010;177(5):2549-62
24. Fuhrmann M, Bittner T, Jung CK, et al. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat Neurosci 2010;13(4):411-13
25. Bhaskar K, Konerth M, Kokiko-Cochran ON, et al. Regulation of tau pathology by the microglial fractalkine receptor. Neuron 2010;68(1):19-31
26. Cho SH, Sun B, Zhou Y, et al. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J Bio Chem 2011;286(37):32713-22
27. Bertollini C, Ragozzino D, Gross C, et al. Fractalkine/CX3CL1 depresses central synaptic transmission in mouse hippocampal slices. Neuropharmacology 2006;51(4):816-21 (Pubitemid 44286937)
28. Heinisch S, Kirby LG. Fractalkine/CX3CL1 enhances GABA synaptic activity at serotonin neurons in the rat dorsal raphe nucleus. Neuroscience 2009;164(3):1210-23
29. Ragozzino D, Di Angelantonio S, Trettel F, et al. Chemokine fractalkine/CX3CL1 negatively modulates active glutamatergic synapses in rat hippocampal neurons. J Neurosci 2006;26(41):10488-98 (Pubitemid 44564599)
30. Soriano SG, Amaravadi LS, Wang YF, et al. Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J Neuroimmunol 2002;125(1-2):59-65 (Pubitemid 34327454)
31. Denes A, Ferenczi S, Halasz J, et al. Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J Cereb Blood Flow Metab 2008;28(10):1707-21
32. Cipriani R, Villa P, Chece G, et al. CX3CL1 is neuroprotective in permanent focal cerebral ischemia in rodents. J Neurosci 2011;31(45):16327-35
33. Liu PY, Lu CL, Wang CC, et al. Spinal microglia initiate and maintain hyperalgesia in a rat model of chronic pancreatitis. Gastroenterology 2012;142(1):165-73; e2
34. Maggi L, Scianni M, Branchi I, et al. CX(3)CR1 deficiency alters hippocampal-dependent plasticity phenomena blunting the effects of enriched environment. Front Cell Neurosci 2011;5:22
35. Rogers JT, Morganti JM, Bachstetter AD, et al. CX3CR1 deficiency leads to impairment of hippocampal cognitive function and synaptic plasticity. J Neurosci 2011;31(45):16241-50